Press Releases

<< Back
Jul 26, 2021

Ziopharm Oncology to Report Second Quarter Financial Results on August 9, 2021

BOSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that management will host a conference call and webcast on Monday, August 9, at 4:30 p.m. EDT to provide a corporate update and discuss financial results for the second quarter ended June 30, 2021.

The conference call can be accessed by dialing 877-451-6152 (U.S. and Canada) or 201-389-0879 (International). The passcode for the conference call is 13721210. A live webcast may be accessed using the link here, or by visiting the “Investors” section of the Ziopharm website at The call will be recorded and available for replay on the Company’s website for approximately 90 days after the call.

About Ziopharm Oncology, Inc.
Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body’s immune system to treat the millions of people globally diagnosed with cancer each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology. Ziopharm’s pipeline is built for commercially scalable, cost-effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic collaborations with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Regeneron Pharmaceuticals. For more information, please visit

Investor Relations Contact:
Adam D. Levy, Ph.D., MBA
EVP, Corporate Development and Investor Relations
T: 508.552.9255

Primary Logo

Source: ZIOPHARM Oncology Inc